Goals and Duration of Treatment for Elderly Patients with Transplant-Ineligible NDMM
The panel explains their goals of treatment for older patients with transplant-ineligible multiple myeloma, and how they determine treatment duration.
Treatment Regimens for Frail Patients with Transplant-Ineligible NDMM
Rafael Fonseca, MD, and Krina Patel, MD, discuss the standard treatment approaches for frail or elderly patients with transplant-ineligible multiple myeloma.
Evaluating MRD-Guided Therapy in Patients with NDMM
Dr Cindy Varga explains the design and results of the MASTER study presented at ASH [American Society of Hematology Annual Meeting] 2021.
Induction Regimens in Transplant-Eligible NDMM: Clinical Trial Data
Comprehensive insight on mainstay induction therapy options for patients with transplant-eligible newly diagnosed multiple myeloma in the context of recent clinical studies.
Patient Case 1: A 54-Year-Old Woman With Transplant-Eligible NDMM
Opening their discussion on the first patient case, expert panelists review the management of transplant-eligible newly diagnosed multiple myeloma.
Findings From LUSTRE Trial Confirm SBRT a ‘Good Alternative’ to Conventional Radiation for Inoperable Lung Cancer, Says Expert
Data from the phase 3 LUSTRE trial indicated that stereotactic body radiotherapy is a safe and effective alternative to conventional radiation for use in patients with stage I medically-inoperable non-small lung cancer, according to an expert from Juravinski Cancer Centre in Canada.
Jyoti S. Mayadev, MD, Discusses Future Directions Within the Cervical Cancer Space
Jyoti S. Mayadev, MD, indicated that future research for cervical cancer will be focused on combination immune checkpoint inhibitors and biomarker research.
Benjamin H. Lowentritt, MD, FACS, Discusses How 18F-rhPSMA-7.3 PET Expands the Armamentarium for Suspected Recurrent Prostate Cancer
Novel PSMA-targeting PET ligand 18F-rhPSMA-7.3 adds to the recurrent prostate cancer armamentarium, according to Benjamin H. Lowentritt, MD, FACS.
Ghassan K. Abou-Alfa, MD, Discusses Importance of Treatment Accessibility in Unresectable HCC
Ghassan K. Abou-Alfa, MD, discusses the importance of improving access to novel therapies and combinations for patients with hepatocellular carcinoma across the world.
Jyoti S. Mayadev, MD, Details Durvalumab’s Impact on Treatment Exposure/Delivery in Combination With CRT in Locally Advanced Cervical Cancer
Durvalumab appeared to have no impact on the ability to deliver safe and timely radiation therapy to patients with high-risk locally advanced cervical cancer, according to Jyoti S. Mayadev, MD.
First-Line Treatment Options in Transplant-Ineligible NDMM
Dr Caitlin Costello presents the case of a patient with transplant-ineligible multiple myeloma and sparks a conversation on the available treatment regimens.
Measuring Treatment Response in Transplant-Eligible NDMM
A look at how to measure an adequate treatment response in patients with transplant-ineligible newly-diagnosed multiple myeloma, and treatment regimens for high-risk patients.
Consolidation and Maintenance Therapy in Transplant-Eligible NDMM
A brief discussion on the use of consolidation therapy to improve patient outcomes following transplant in newly diagnosed multiple myeloma.
Selecting the Optimal Induction Therapy in Transplant-Eligible Newly Diagnosed Multiple Myeloma
Expert perspectives on the real-world use of induction therapy and transplant in patients with transplant-eligible newly diagnosed multiple myeloma.
Cross Q&A: Belantamab for Multiple Myeloma Treatment
Malin Hultcrantz, MD, PhD, questions Shonali Midha, MD, about the data she presented on belantamab mafodotin in patients with relapsed/refractory multiple myeloma.
Ponatinib after TKI Failure in Chronic Myeloid Leukemia
Dr DeAngelo shares data on the use of ponatinib for CML treatment after failure of second-generation TKIs.
Asciminib vs Bosutinib in Chronic Myeloid Leukemia Treatment
Daniel DeAngelo, MD, PhD, presents data from a phase 3 study comparing asciminib and bosutinib after treatment with 2 or more prior TKIs in CML.
Data on Real-World Use of Belantamab Mafodotin in R/R MM
Dr Shonali Midha continues her analysis of belantamab mafodotin with a look at data on real-world use in R/R MM since its FDA approval in August 2020.
Optimizing Selection of ADC Therapy in Metastatic Urothelial Carcinoma
Focused discussion on the optimal selection and use of antibody-drug conjugate therapies in patients with metastatic urothelial carcinoma.
Sequencing Therapy Through Multiple Lines of Metastatic Urothelial Carcinoma
Expert perspectives on treatment sequencing pathways in metastatic urothelial carcinoma, with deference to recent trial data for both IO and ADC therapies.
